A novel p34cdc2-binding and activating protein that is necessary and sufficient to trigger G2/M progression in Xenopus  oocytes by Ferby, Ingvar et al.
A novel p34cdc2-binding and activating
protein that is necessary and sufficient
to trigger G2/M progression
in Xenopus oocytes
Ingvar Ferby, Montserrat Blazquez, Amparo Palmer, Ramon Eritja, and Angel R. Nebreda1
European Molecular Biology Laboratory, 69117 Heidelberg, Germany
The activation of maturation-promoting factor (MPF) is required for G2/M progression in eukaryotic cells.
Xenopus oocytes are arrested in G2 and are induced to enter M phase of meiosis by progesterone stimulation.
This process is known as meiotic maturation and requires the translation of specific maternal mRNAs stored
in the oocytes. We have used an expression cloning strategy to functionally identify proteins involved in
G2/M progression in Xenopus oocytes. Here we report the cloning of two novel cDNAs that when expressed
in oocytes induce meiotic maturation efficiently. The two cDNAs encode proteins of 33 kD that are 88%
identical and have no significant homologies to other sequences in databases. These proteins, which we refer
to as p33ringo (rapid inducer of G2/M progression in oocytes), induce very rapid MPF activation in
cycloheximide-treated oocytes. Conversely, ablation of endogenous p33ringo mRNAs using antisense
oligonucleotides inhibits progesterone-induced maturation, suggesting that synthesis of p33ringo is required for
this process. We also show that p33ringo binds to and activates the kinase activity of p34cdc2 but does not
associate with p34cdc2/cyclin B complexes. Our results identify a novel p34cdc2 binding and activating protein
that regulates the G2/M transition during oocyte maturation.
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Entry of eukaryotic cells into M phase of the cell cycle is
regulated by maturation-promoting factor (MPF), an ac-
tivity composed of a B-type cyclin and the protein kinase
p34cdc2. Cyclin B is usually synthesized and associates
with p34cdc2 throughout late S phase and early G2, but
the p34cdc2/cyclin B complex is maintained inactive by
the phosphorylation of p34cdc2 on Thr-14 and Tyr-15.
Dephosphorylation of p34cdc2 leads to activation of the
MPF kinase activity, which can phosphorylate many
proteins responsible for both the G2/M transition and
progression through M phase (for review, see Nurse
1990; Coleman and Dunphy 1994; Morgan 1997).
Xenopus oocytes are naturally arrested in late G2 and
are induced to enter into M phase of meiosis by proges-
terone. This process is known as meiotic maturation and
is associated with the activation of MPF (Masui and
Clarke 1979). In G2-arrested Xenopus oocytes there is a
preformed stock of p34cdc2/cyclin B complexes (pre-
MPF) that is maintained inactive by the phosphorylation
of p34cdc2 on Thr-14 and Tyr-15 (Cyert and Kirschner
1988; Gautier and Maller 1991; Kobayashi et al. 1991b).
The inhibitory phosphorylation of p34cdc2 in immature
oocytes is likely to be due to the membrane-bound pro-
tein kinase Myt1 (Atherton-Fessler et al. 1994; Korn-
bluth et al. 1994; Mueller et al. 1995; Palmer et al. 1998),
whereas the activating dephosphorylation probably in-
volves the phosphatase Cdc25 (Dunphy and Kumagai
1991; Gautier et al. 1991; Kumagai and Dunphy 1991;
Strausfeld et al. 1991). Thus, either an increased activity
of Cdc25 or the inhibition of Myt1 may bring about the
activation of pre-MPF during oocyte maturation.
An essential requirement for progesterone-induced
maturation is the translation of maternal mRNAs stored
in the oocyte. Although several mRNAs are known to be
translated de novo during oocyte maturation (Sagata et
al. 1988; Kobayashi et al. 1991b; Gabrielli et al. 1992;
Rempel et al. 1995; Murakami and Vande Woude 1998),
only the mRNA encoding the protein kinase p39mos has
been found so far to be necessary for oocyte maturation
(Sagata et al. 1988, 1989; Freeman et al. 1990; Sheets et
al. 1995). Injection of either p39mos mRNA or recombi-
nant p39mos protein into Xenopus oocytes induces matu-
ration in the absence of progesterone (Sagata et al. 1988,
1989; Yew et al. 1992). Conversely, injection of p39mos
antisense oligonucleotides blocks progesterone-induced
MPF activation indicating that p39mos is necessary for
the initiation of maturation (Sagata et al. 1988).
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The function of p39mos in oocyte maturation is most
likely related to its ability to activate the p42mpk1 MAP
kinase pathway (Nebreda et al. 1993; Nebreda and Hunt
1993; Posada et al. 1993; Shibuya and Ruderman 1993).
This is supported by the injection of neutralizing anti-
MAP kinase kinase antibodies that inhibit p39mos-in-
duced oocyte maturation (Kosako et al. 1994, 1996) and
is also consistent with the observation that upon ectopic
p39mos expression, activation of p42mpk1 always pre-
cedes the activation of pre-MPF (Nebreda and Hunt
1993; Posada et al. 1993; Shibuya and Ruderman 1993).
The idea that activation of p42mpk1 plays an important
role in meiotic maturation is further supported by the
delay in progesterone-induced maturation observed upon
injection of either anti-MAP kinase kinase antibodies
(Kosako et al. 1994, 1996) or a specific MAP kinase phos-
phatase (Gotoh et al. 1995). Conversely, microinjection
of constitutively active MAP kinase kinase (Huang et al.
1995) or active thiophosphorylated p42mpk1 (Haccard et
al. 1995) can induce oocyte maturation in the absence of
progesterone. Taken together, the results suggest that
activation of the p42mpk1 cascade may be both necessary
and sufficient to release the oocyte from the G2-phase
arrest. A possible connection between the activation of
p42mpk1 and MPF during oocyte maturation may be pro-
vided by the p42mpk1-activated protein kinase p90rsk,
which can phosphorylate and down-regulate Myt1
(Palmer et al. 1998).
In spite of the central role of p39mos and the p42mpk1
pathway in oocyte maturation, there is evidence that
synthesis of other proteins in addition to p39mos is also
required for progesterone to initiate oocyte maturation
(Nebreda et al. 1995; Barkoff et al. 1998). Thus, in many
batches of oocytes, the ability of p39mos or a constitu-
tively active MAP kinase kinase mutant to activate pre-
MPF is significantly reduced when protein synthesis is
inhibited, whereas p42mpk1 is normally activated under
these conditions (Yew et al. 1992; Daar et al. 1993; Ne-
breda and Hunt 1993; Shibuya and Ruderman 1993;
Huang et al. 1995; Murakami and Vande Woude 1997).
These data indicate that p42mpk1 activation alone is not
always sufficient to activate pre-MPF. In contrast, the
ability of recombinant cyclin A to activate pre-MPF is
the same when injected into either untreated or cyclo-
heximide-treated oocytes (Nebreda et al. 1995). Further-
more, overexpression of a dominant-negative p34cdc2
mutant or injection of a neutralizing anti-p34cdc2 anti-
body blocks progesterone-induced p39mos accumulation
and the activation of both p42mpk1 and MPF (Nebreda et
al. 1995). These results were taken to suggest that acti-
vation of the free p34cdc2 present in the oocyte (which is
in a notable excess over the p34cdc2 complexed with cy-
clin B) is normally required for progesterone-induced
maturation. However, there is no evidence that newly
synthesized A- and B-type cyclins, which would be the
obvious candidates to activate free p34cdc2, are required
for progesterone-induced MPF activation (Minshull et al.
1991).
In this paper we have used an expression cloning strat-
egy to identify novel proteins that can trigger oocyte
maturation. We have cloned two cDNAs that upon ex-
pression in oocytes (either as synthetic mRNAs or re-
combinant proteins), can potently induce MPF activa-
tion and germinal vesicle breakdown (GVBD) in the ab-
sence of progesterone. Moreover, antisense-directed
ablation of the endogenous mRNAs in the oocyte inhib-
its progesterone-induced maturation. These cDNAs code
for closely related proteins that can bind to and activate
the protein kinase p34cdc2. Our results indicate that this
novel p34cdc2 binding and activating protein plays an im-
portant role in oocyte maturation.
Results
Cloning of two novel cDNAs that potently induce
G2/M progression in Xenopus oocytes
To identify novel proteins involved in G2/M progression
during the meiotic maturation of Xenopus oocytes, we
used an expression cloning strategy in which we con-
structed a Xenopus oocyte cDNA library in the FTX5
expression vector. The primary library was subdivided
into pools of 150–200 colonies and plasmid DNA was
purified from the pools and in vitro transcribed to obtain
mRNAs. The mRNA pools that upon microinjection
into oocytes were able either to induce oocyte matura-
tion on their own or to accelerate progesterone-induced
maturation were subdivided into smaller pools and rein-
jected until single positive clones were isolated. Using
this approach, we isolated two clones named ls26 and
ls27, which by DNA hybridization experiments did not
correspond to proteins that are known to induce oocyte
maturation including p39mos, Cdc25, and several A- and
B-type cyclins (data not shown). The mRNAs prepared
from the ls26 and ls27 clones were able to induce oocyte
maturation in the absence of progesterone stimulation,
even at concentrations as low as 250 pg per oocyte (Fig.
1A, left), as well as to significantly accelerate progester-
one-induced maturation at a 10-fold lower concentration
(Fig. 1A, right). Oocyte maturation induced by expres-
sion of ls26 or ls27 was accompanied by the appearance
of a white spot at the animal pole of the oocyte as in
progesterone-matured oocytes (Fig. 2), although a few
hours later ls26/ls27-injected oocytes usually appeared
‘overmatured’. This overmaturation is sometimes simi-
larly observed upon injection of high concentrations of
cyclin A or p39mos (not shown). As in progesterone-
treated oocytes, the maturation induced by ls26 or ls27
correlated with the activation of both p42mpk1 MAP ki-
nase (p42mpk1 is phosphorylated resulting in an upward
shift in immunoblots) and p34cdc2/cyclin B (pre-MPF,
p34cdc2 is dephosphorylated resulting in a downward
shift in immunoblots) as well as with the appearance of
p39mos (Fig. 1B). We also found that ls26 and ls27 were
able to induce oocyte maturation faster than p39mos,
based on experiments where all mRNAs were prepared
from the same expression vector and injected into oo-
cytes at equivalent concentrations (Fig. 1C).
DNA sequencing of the clones isolated from the ex-
pression library showed that the ls26 and ls27 open read-
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ing frames (ORFs) encoded related proteins that were
fused in-frame to the carboxyl terminus of the myc tag in
the FTX5 vector. Using the partial cDNAs as probes, we
cloned full-length cDNAs from a l ZAP Xenopus oocyte
cDNA library. The ls26 cDNA was 1574 bp long and
encoded a protein of 300 amino acids, whereas ls27 was
1357 bp in length and encoded a protein of 298 amino
acids. Both clones contained stop codons upstream of the
first ATG and in the same frame. The predicted ls26 and
ls27 proteins were 88% identical (Fig. 3). The cDNAs
isolated from the oocyte expression screening encoded
Myc-tagged proteins that either lacked the first 11 amino
acids (ls26) or had an amino-terminal extension of 24
amino acids corresponding to the 58-untranslated region
(ls27). In a search of the ls26 and ls27 sequences using
BLAST against DNA and protein sequence databases, we
could detect no significant homologies, suggesting that
ls26/ls27 belonged to a novel protein family. We were
also unable to identify conserved protein motifs using
PROSITE and GENEQUIZ programs. The only poten-
tially relevant homologies were obtained from expressed
sequence-tag (EST) databases. The best score in these
searches was for the human EST clone 757814, which
was 53% identical over a 49-amino-acid stretch. In con-
trast, no homologs were detected in the budding yeast
genome. The close similarity between the sequences of
ls26 and ls27 suggests that they might correspond to
pseudoalloploid alleles; because they induced oocyte
maturation with the same efficiency, we concentrated
on ls26 for further characterization. We named this pro-
tein p33ringo for rapid inducer of G2/M progression in
oocytes.
Recombinant p33ringo can trigger GVBD and MPF
activation in cycloheximide-treated oocytes
To further characterize the ability of p33ringo to induce
oocyte maturation, we prepared a maltose-binding pro-
tein (malE)–p33ringo fusion protein. We found that the
injection of 40 ng of bacterially produced malE–p33ringo
was able to induce oocyte maturation considerably faster
than progesterone treatment; 50% GVBD usually took
~ 2.5 hr with malE–p33ringo versus 5–11 hr with proges-
terone. Moreover, injection of only 10 ng of malE–
p33ringo per oocyte was still able to induce maturation in
100% of the injected oocytes (see Fig. 6a, below). We also
Figure 2. Morphological appearance of p33ringo mRNA-in-
jected oocytes (50 ng/oocyte) after 2.5 and 5 hr of incubation.
Oocytes treated with progesterone (5 µg/ml) for 10 hr and con-
trol (water-injected) oocytes are shown.
Figure 1. Induction of Xenopus oocyte maturation
by a novel protein. (A) The indicated concentrations
(total amount per oocyte) of mRNA transcribed in
vitro from the ls26 cDNA were injected into oocytes
and GVBD was scored (left). Progesterone was added
to the groups of injected oocytes that showed no
white spot after 18 hr of incubation (right). Similar
results were observed with mRNA prepared from
the ls27 cDNA (not shown). (B) Immunoblot analysis
using anti-p42mpk1, anti-p34cdc2, and anti-p39mos
antibodies of lysates prepared from oocytes (four
oocytes per time point) either untreated (control),
treated with progesterone (5 µg/ml), injected with
in vitro-transcribed mRNA encoding for p33ringo
(ls26, 50 ng/oocyte) or both injected with mRNA
encoding for p33ringo and treated with progester-
one. In this experiment 50% GVBD was observed
at 10, 3.5, and 1.5 hr with progesterone, p33ringo,
and p33ringo + progesterone, respectively. (C) Oo-
cytes were either injected with in vitro-transcribed
mRNAs (500 pg/oocyte) encoding Myc-tagged forms
of the two isoforms of p33ringo (ls26 and ls27) and
p39mos or treated with progesterone (5 µg/ml) and
then GVBD was scored.
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tested whether malE–p33ringo was able to induce oocyte
maturation in the presence of protein synthesis inhibi-
tors. Preincubation of the oocytes with cycloheximide
(10 µg/ml) is known to block progesterone-induced
maturation, consistent with the known essential re-
quirement for de novo translation of maternal mRNAs.
However, we found that cycloheximide had no effect on
the ability of malE–p33ringo to induce MPF activation
and GVBD (Fig. 4).
We investigated the kinetics of activation of p42mpk1
and p34cdc2/cyclin B in oocytes induced to mature by
malE–p33ringo. Consistent with previous work, proges-
terone treatment activated both p42mpk1 and pre-MPF at
the same time, whereas malE–p39mos injection activated
p42mpk1 before pre-MPF (Fig. 4). In contrast, injection of
malE–p33ringo rapidly activated histone H1 kinase
(which correlated with Tyr dephosphorylation of
p34cdc2) somewhat before myelin basic protein (MBP) ki-
nase activity and p42mpk1 phosphorylation, indicating
that p34cdc2/cyclin B preceded p42mpk1 activation. Inter-
estingly, the ability of malE–p33ringo to activate p34cdc2/
cyclin B, as determined by both increased histone H1
kinase activity and disappearance of the band with re-
duced electrophoretic mobility in p34cdc2 immunoblots,
was unaffected in the presence of cycloheximide (Fig. 4).
In these oocytes, however, the kinase activity on histone
H1 was not stable and decreased after GVBD (Fig. 4) sug-
gesting that p34cdc2/cyclin B might be transiently acti-
vated by p33ringo in cycloheximide-treated oocytes. On
the other hand, oocytes injected with malE–p33ringo in
the presence of cycloheximide had no detectable MBP
kinase activity and most of their p42mpk1 was unphos-
phorylated, suggesting that activation of p42mpk1 was
very much reduced (Fig. 4). This observation suggests
that the activation of p42mpk1 by p33ringo may be the
consequence of positive feedback loops that are blocked
by cycloheximide. Thus, the function of p33ringo is more
likely to be related to the activation of p34cdc2 rather
than of p42mpk1. We also found that as in the case of
progesterone and p39mos, oocyte maturation induced by
p33ringo involves de novo synthesis of cyclins B1 and B4
(Fig. 4).
p33ringo is required for progesterone-induced oocyte
maturation
To evaluate the importance of p33ringo for oocyte matu-
ration we used antisense oligonucleotides. We first
tested the oligonucleotides in an in vitro system and
found that some antisense but not the control oligo-
nucleotides could efficiently target the two isolated
p33ringo clones (Fig. 5A, ls26 and ls27). The p33ringo an-
tisense oligonucleotides, however, did not trigger degra-
dation of the synthetic p39mos mRNA under the same
Figure 3. Amino acid sequence comparison of the
ls26 and ls27 p33ringo clones. Identity is indicated by
a vertical bar.
Figure 4. MPF activation by recombinant malE–
p33ringo in cycloheximide-treated oocytes. Oo-
cytes were injected with malE–p33ringo (40 ng) or
malE–p39mos (40 ng), or treated with progesterone
(5 µg/ml) in the presence or absence of 10 µg/ml
cycloheximide, as indicated. Cycloheximide was
added 30 min prior to the injection or progester-
one treatment and maintained during the subse-
quent incubation. At the indicated times, groups
of five oocytes were collected, lysed, and analyzed
both by in vitro kinase assay using as a substrate
either histone H1 or MBP and by immunoblotting
with anti-p42mpk1, anti-p34cdc2, and anti-cyclins
B1 and B4 antibodies.
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conditions (Fig. 5A, p39mos). Next, we injected the
p33ringo antisense oligonucleotides into oocytes and
found that they were able to strongly delay progesterone-
induced oocyte maturation, whereas injection of control
oligonucleotides had no inhibitory effect (Fig. 5B). By
Northern blot we found that the p33ringo antisense oli-
gonucleotides were able to ablate the endogenous
p33ringo mRNA(s) but not the endogenous p39mos mRNA
(Fig. 5C).
To test the specificity of the antisense oligonucleo-
tides, we tried to rescue the inhibition of progesterone-
induced GVBD by adding back small amounts of purified
p33ringo protein. For this experiment, oocytes that had
been injected with control or antisense oligonucleotides
were injected a second time with different amounts of
purified malE–p33ringo prior to progesterone stimulation.
As shown in Figure 6A, the inhibitory effect of the
p33ringo antisense oligonucleotide on progesterone-in-
duced maturation, could be readily reversed by coinjec-
tion of only 2.5 ng of malE–p33ringo, an amount that was
not enough to trigger oocyte maturation in the absence
of progesterone. These results indicate that the p33ringo
Figure 5. Inhibition of progesterone-induced oocyte matura-
tion by p33ringo antisense oligonucleotides. (A) In vitro-tran-
scribed mRNAs encoding the two isoforms of p33ringo (ls26 and
ls27) and p39mos were translated in rabbit reticulocyte lysates
with [35S]methionine either alone (lane 1) or in the presence of
p33ringo antisense oligonucleotides (lanes 2–8) or with control
oligonucleotides (lane 9) and analyzed by SDS-PAGE and auto-
radiography. (B) Oocytes were injected with 100 ng of the indi-
cated oligonucleotides and incubated for 6 hr prior to progester-
one stimulation. GVBD was scored at the indicated times. We
observed essentially the same results in four experiments using
two different oligonucleotide preparations. (C) RNA was ex-
tracted from groups of 20 oocytes taken after 16 hr of incubation
as in B and analyzed by Northern blot using as a probe the
p33ringo cDNA (top). The same RNA blot was reprobed with the
p39mos cDNA (bottom).
Figure 6. Requirement for endogenous p33ringo during proges-
terone-induced oocyte maturation. (A) Oocytes were injected
with 100 ng of either antisense-6 or control-9 oligonucleotides
(indicated by + and −, respectively) and incubated for 6 hr prior
to the injection of the indicated amounts of malE–p33ringo and/
or progesterone stimulation. After 8 hr, GVBD was scored and
groups of five oocytes were taken, lysed, and analyzed by im-
munoblotting with anti-p34cdc2 and anti-p42mpk1 antibodies. (B)
Oocytes were either noninjected or injected with 100 ng of the
indicated oligonucleotides and incubated for 6 hr prior to pro-
gesterone stimulation. After 12 hr, lysates were prepared from
groups of five oocytes and analyzed by immunoblotting using
affinity-purified anti-p33ringo antibodies. In lanes 5 and 6, the
antibodies were preincubated with malE–p33ringo protein before
immunoblotting. The arrow indicates one band that cross-re-
acts with anti-p33ringo antibodies in mature oocytes. (C) Groups
of 25 oocytes were injected with the indicated oligonucleotides
and incubated with [35S]methionine in the presence or absence
of progesterone. After 14 hr, oocytes were lysed and immuno-
precipitated with either preimmune (lanes 1,2) or anti-p33ringo
antiserum (lanes 3–6). The arrows indicate two proteins that are
immunoprecipitated by anti-p33ringo antibodies in mature oo-
cytes.
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antisense oligonucleotides are likely to inhibit proges-
terone-induced oocyte maturation via the specific target-
ing of the endogenous p33ringo mRNA(s).
We also investigated the endogenous p33ringo protein
in oocytes. By immunoblotting with affinity-purified
anti-p33ringo antibodies, we could detect one band of ~ 34
kD in lysates prepared from progesterone-matured oo-
cytes (Fig. 6B, lanes 2,4). This band was not present when
the anti-p33ringo antibodies were preincubated with re-
combinant malE–p33ringo protein (Fig. 6B, lane 6) and
was neither detected when the oocytes were injected
with p33ringo antisense oligonucleotides prior to proges-
terone stimulation (Fig. 6B, lane 3). This indicates that
the 34-kD protein was recognized specifically by the
anti-p33ringo antibodies and that its appearance corre-
lated with oocyte maturation.
Further evidence that p33ringo was synthesized during
oocyte maturation was obtained by immunoprecipita-
tion with anti-p33ringo antibodies of metabolically la-
beled oocytes. In these experiments we could detect two
[35S]methionine-labeled proteins of ~ 34 and 37 kD in ly-
sates prepared from progesterone-matured oocytes (Fig.
6C, lane 4). These two proteins were immunoprecipi-
tated neither from lysates of G2-arrested oocytes (Fig.
6C, lane 3) nor from lysates of oocytes injected with
p33ringo antisense oligonucleotides prior to progesterone
stimulation (Fig. 6C, lane 6), in agreement with the in-
hibitory effect of the oligonucleotides. These results in-
dicate that the synthesis of p33ringo is up-regulated dur-
ing progesterone-induced oocyte maturation.
p33ringo can associate independently with both p34cdc2
and cyclin B but not with p34cdc2/cyclin B complexes
The observation that p33ringo induced GVBD and the ac-
tivation of MPF independently of new protein synthesis
indicated that it was likely to act rather late in the sig-
naling pathways that lead to the activation of pre-MPF.
We investigated the possibility that p33ringo could di-
rectly associate with and/or modify the activity of
p34cdc2/cyclin B complexes. Initially, we used extracts
prepared from insect cells infected with p34cdc2-express-
ing baculovirus for pull-down experiments with malE–
p33ringo bound to amylose beads. In these experiments
we could detect that p34cdc2 bound to malE–p33ringo but
not to malE alone (Fig. 7A, lanes 3–6). Moreover, when
soluble cyclin B was added to the p34cdc2-containing ex-
tract prior to the amylose pull-down, we could still de-
tect about the same amount of p34cdc2 bound to p33ringo
but no cyclin B (Fig. 7A, lanes 7–10). This suggests that
p33ringo did not bind efficiently to the p34cdc2/cyclin B
complex and might preferentially bind to free p34cdc2.
We also detected some binding of cyclin B to malE–
p33ringo in the absence of p34cdc2 (Fig. 7A, lanes 11–14).
In parallel experiments, we used Ni beads to directly
recover the His-tagged cyclin B and found that when the
cyclin B pull-down was done in the presence of a two-
fold molar excess of soluble malE–p33ringo, there was a
reduction in the amount of p34cdc2 bound to cyclin B
(data not shown), suggesting that p33ringo might compete
with cyclin B for binding to p34cdc2.
The interaction between p33ringo and p34cdc2 was con-
firmed using [35S]methionine-labeled proteins prepared
Figure 7. Interaction of p33ringo with free p34cdc2 and cyclin B
but not with p42mpk1. (A) Purified malE–p33ringo (2, 0.2, and 0.02
µg) or malE (2 µg) was prebound to amylose beads and incubated
with p34cdc2-expressing insect cell extracts (containing ~ 10 µg
of p34cdc2, lanes 3–6), purified His–cyclin B (8 µg, lanes 11–14) or
p34cdc2-expressing extracts plus His–cyclin B (lanes 7–10). After
extensive washing, the bead-associated proteins were analyzed
by immunoblot with anti-p34cdc2 and anti-penta-His antibodies.
Aliquots of the p34cdc2-expressing extract (lane 1) and purified
His–cyclin B (lane 2) before the pull-down were also analyzed in
the same immunoblot. (B) [35S]-Labeled p34cdc2, cyclin B1, cyc-
lin B2, or p42mpk1 prepared in rabbit reticulocyte lysates was
incubated with 1 µg of malE or malE–p33ringo bound to amylose
beads. After extensive washing, the beads were analyzed by
SDS-PAGE followed by autoradiography. (C) Lysates prepared
from 20 control or progesterone-treated oocytes were incubated
with malE or malE–p33ringo prebound to amylose beads, exten-
sively washed, and analyzed by SDS-PAGE and immunoblot-
ting with anti-p34cdc2 and anti-p42mpk1 antibodies. Aliquots of
the lysates before the pull-downs (corresponding to one oocyte)
were analyzed in the same gel (extracts).
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in rabbit reticulocyte lysates for malE–p33ringo pull-
down experiments (Fig. 7B). We also observed in these
experiments that p33ringo bound to cyclins B1 and B2 but
did not bind to p42mpk1 significantly (Fig. 7B).
To extend these observations, we investigated
whether p33ringo could also bind to the endogenous
p34cdc2 in Xenopus oocytes. We found that p34cdc2 was
present in malE–p33ringo pull-downs prepared from oo-
cyte extracts (Fig. 7C, lanes 4, 6) but not in the malE
pull-downs prepared in parallel from the same extracts
(Fig. 7C, lanes 3, 5). Moreover, it appeared that the ma-
jority of the p34cdc2 bound to p33ringo might be free
p34cdc2 rather than p34cdc2 complexed with cyclin B,
based on the electrophoretic motility of the p34cdc2 iso-
lated from immature oocytes (Fig. 7C). The binding of
p33ringo to free p34cdc2 was also supported by the lack of
detection of cyclin B1 in the p33ringo pull-downs pre-
pared from progesterone-matured oocytes (data not
shown). Because endogenous B-type cyclins in the oo-
cytes are likely to be mostly bound to p34cdc2 (Kobayashi
et al. 1991b), this is consistent with p33ringo not being
able to associate efficiently with p34cdc2/cyclin B com-
plexes. In these experiments we confirmed that p33ringo
did not bind to the endogenous p42mpk1 in oocyte ex-
tracts (Fig. 7C).
Activation of p34cdc2 by p33ringo in cell-free extracts
and in vitro
To gain further information on the possible function of
p33ringo in oocyte maturation, we used cell-free extracts
prepared by high speed centrifugation of oocyte lysates
(Karaiskou et al. 1998). Addition of recombinant Cdc25
to these extracts can trigger the activation of p34cdc2/
cyclin B complexes as indicated by the detection of H1
kinase activity and the disappearance of the slowly mi-
grating p34cdc2 band in immunoblots (Fig. 8A, lanes 5, 6).
As expected, the activity of Cdc25 was blocked by vana-
date (Fig. 8A, lanes 11, 12). In contrast, p33ringo could
induce the rapid appearance (5 min) of histone H1 kinase
activity, which did not correlate with any change in the
electrophoretic mobility of p34cdc2 in immunoblots (Fig.
8A, lanes 3, 4) and was not affected by the presence of
vanadate (Fig. 8A, lanes 9, 10). Interestingly, Cdc25 and
p33ringo appeared to have an additive effect on the level
of H1 kinase activity (Fig. 8A, lanes 7, 8). Taken together,
the results suggest that p33ringo can stimulate the H1
kinase activity of free p34cdc2.
To confirm the activation of free p34cdc2 by p33ringo,
we investigated the ability of malE–p33ringo to stimulate
the kinase activity of p34cdc2 in cell-free extracts pre-
pared from baculovirus-infected insect cells. For this ex-
periment, we added either cyclin B, malE–p33ringo, or
malE alone to insect cell extracts containing p34cdc2 and
then assayed their histone H1 kinase activity in vitro
(Fig. 8B). We found that both cyclin B and malE–p33ringo,
but not malE alone, up-regulated the histone H1 kinase
activity of the p34cdc2-expressing extracts (Fig. 8B, lanes
1–7). In contrast, the increase in histone H1 kinase ac-
tivity was very much reduced when we used extracts
containing a kinase-inactive p34cdc2 mutant (p34cdc2
K33R) instead of wild-type p34cdc2 (Fig. 8B, lanes 8–10).
Moreover, the histone H1 kinase activity triggered by
either cyclin B or malE–p33ringo was recovered on p13suc1
beads (data not shown), suggesting further that it was
due to the activation of p34cdc2. We also observed in-
creased histone H1 kinase activity upon addition of
malE–p33ringo to interphase Xenopus extracts prepared
from activated eggs, where cyclins have been degraded
and there are no preformed p34cdc2/cyclin complexes but
only free p34cdc2 (not shown). On the other hand, p33ringo
did not modify the histone H1 kinase activity of purified
p34cdc2/cyclin B complexes (data not shown).
We also investigated whether malE–p33ringo was able
to directly activate bacterially produced GST–p34cdc2.
Incubation of the two recombinant proteins together in a
buffer containing Mg/ATP did not result in any measur-
able kinase activity on histone H1 (data not shown).
However, addition of malE–p33ringo to GST–p34cdc2,
which had been preincubated in interphase Xenopus ex-
tracts and then recovered on glutathione beads, resulted
in a significant increase in histone H1 kinase activity
(Fig. 8C). These results suggest that p33ringo may be able
to directly activate p34cdc2, although it is also possible
that additional factors might have been recruited from
the cell-free extract by the GST–p34cdc2.
A kinase-inactive p34cdc2 K33R mutant inhibits
p33ringo-induced oocyte maturation
The above results suggested that p33ringo may trigger oo-
cyte maturation by binding to and activating free
p34cdc2. This possibility was supported by the observa-
tion that malE–p33ringo-induced maturation was inhib-
ited by overexpression in oocytes of the kinase-inactive
p34cdc2 K33R mutant (injection of synthetic mRNA re-
sults in about six times more p34cdc2 K33R than the
endogenous p34cdc2 concentration) (Nebreda et al. 1995).
In contrast, overexpression of wild-type p34cdc2 did not
affect oocyte maturation induced by injection of malE–
p33ringo (Fig. 8D). We also found that coinjection of a
small amount of malE–p33ringo was able to rescue the
inhibitory effect of p34cdc2 K33R on progesterone-in-
duced maturation (Fig. 8D). This suggests that titration
of endogenous p33ringo may account for the previously
reported inhibition of progesterone-induced oocyte
maturation by p34cdc2 K33R (Nebreda et al. 1995).
Discussion
In this report we describe the cloning and characteriza-
tion of p33ringo, a novel protein that can efficiently in-
duce entry into M phase of meiosis in Xenopus oocytes.
At low concentrations p33ringo does not trigger matura-
tion alone but strongly accelerates progesterone-induced
maturation, suggesting that the pathway stimulated by
p33ringo is normally activated during oocyte maturation.
The induction of bona fide oocyte maturation by p33ringo
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is supported by the appearance of the characteristic
white spot at the animal pole of oocytes and the detec-
tion of the same biochemical markers as in progesterone-
matured oocytes, including the appearance of p39mos,
cyclins B1 and B4, and the activation of both p42mpk1 and
pre-MPF. We also observed that the oocytes injected
with p33ringo tend to overmature to various extents after
longer incubations, depending on the oocyte batch. This
has been observed similarly upon overexpression in oo-
cytes of other proteins that can trigger maturation such
as p39mos or cyclin A (A.R. Nebreda, unpubl.) and is
probably due to some side effects generated by the high
levels of ectopic protein.
The ability of recombinant p33ringo to induce MPF ac-
tivation and GVBD independently of protein synthesis
indicates that it does not function by stimulating the
translation of maternal mRNAs encoding p39mos or
other triggering proteins (Barkoff et al. 1998). Moreover,
the observation that p42mpk1 activation by p33ringo is
strongly reduced by the presence of cycloheximide sug-
gests that p33ringo is likely to function closer to the ac-
tivation of p34cdc2 than of p42mpk1. Consistent with this
idea, recombinant cyclin A or Cdc25 can also induce
MPF activation and GVBD very potently, independently
of protein synthesis but only activate p42mpk1 when pro-
tein synthesis is allowed (Nebreda et al. 1995). In con-
trast, the ability of activators of the p42mpk1 pathway to
induce MPF activation in cycloheximide-treated oocytes
versus nontreated oocytes is often reduced (see introduc-
tory section). In spite of the potent activity of p33ringo to
induce MPF activation and GVBD in the presence of cy-
cloheximide, the histone H1 kinase activity in these oo-
cytes appears to be activated only transiently. This sug-
gests that the oocytes enter into meiosis I but are unable
to proceed through meiosis II and arrest at the meiotic
interphase with low levels of MPF (and, hence, histone
H1 kinase) activity. It therefore appears that synthesis of
additional proteins is necessary for entry into meiosis II.
Similar observations have been reported when p39mos
protein is injected in the presence of cycloheximide (Mu-
rakami and Vande Woude 1997).
The experiments using antisense oligonucleotides sug-
gest that the endogenous p33ringo mRNA is required for
progesterone to induce oocyte maturation. Moreover, in-
jection of small doses of recombinant malE–p33ringo,
which cannot trigger oocyte maturation in the absence
of progesterone, can rescue the inhibitory effect of the
antisense oligonucleotides indicating that they are un-
likely to target other important mRNAs. These results,
together with the observation that synthesis of p33ringo
is up-regulated upon progesterone stimulation, indicate
that de novo synthesis of p33ringo is likely to be required
for progesterone-induced maturation. We have also ob-
served that antisense-directed interference with either
p33ringo or p39mos mRNAs alone significantly delays pro-
gesterone-induced maturation but usually does not to-
tally block the process (Fig. 5; data not shown). Thus,
although synthesis of both p33ringo and p39mos may be
normally required for progesterone-induced maturation,
it appears that synthesis of only one of them can still
trigger oocyte maturation albeit with reduced efficiency.
Figure 8. Activation of free p34cdc2 by p33ringo and inhibition
of p33ringo-induced GVBD by kinase-inactive p34cdc2 K33R. (A)
High-speed oocyte extracts (25 µl) were incubated with 1 µg of
malE (lanes 1,2), 0.6 µg of malE–p33ringo (lanes 3,4,9,10), 0.2 µg
GST–Cdc25 (lanes 5,6,11,12), or both malE–p33ringo and GST–
Cdc25 (lanes 7,8). Where indicated (lanes 9–12), 5 mM vanadate
was added 5 min prior to the addition of the recombinant pro-
teins. At the indicated times, aliquots (5 µl) were withdrawn
and analyzed both by in vitro kinase assay on histone H1 and by
immunoblotting with anti-p34cdc2 antibodies. The phosphory-
lation of histone H1 was quantified in a PhosphorImager. (B)
Insect cell extracts containing either wild-type p34cdc2 (lanes
1–7) or p34cdc2 K33R (lanes 8–10) were incubated with malE (75
µg/ml, lanes 1,8), malE–p33ringo (75 µg/ml, lanes 2,9; 7.5 µg/ml,
lane 3; 0.75 µg/ml, lane 4) or His–cyclin B (50 µg/ml, lanes 5,10;
5 µg/ml, lane 6; 0.5 µg/ml, lane 7). After 20 min, histone H1
kinase activity in the total extracts was assayed. (C) Interphase
Xenopus extracts either alone (lanes 1,3,5) or containing bacte-
rially produced GST–p34cdc2 (1.5 µg, lanes 2,4,6) were incubated
with glutathione–Sepharose beads. After centrifugation, the
beads were washed extensively and incubated with 2 µg of ei-
ther malE (lanes 1,2), malE–p33ringo (lanes 3,4), or His–cyclin B
(lanes 5,6) for 20 min at 22°C and then used for histone H1
kinase assays. (D) Oocytes were injected with in vitro-tran-
scribed mRNAs encoding either wild-type p34cdc2 or p34cdc2
K33R (Nebreda et al. 1995) and incubated for 16 hr prior to the
injection of the indicated amounts of malE–p33ringo and/or pro-
gesterone stimulation. GVBD was scored after 14 hr.
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How can p33ringo trigger oocyte maturation? The
amino acid sequence of p33ringo is not very informative
as it shows no significant homologies to other proteins
in databases. An interesting clue, however, is the ability
of p33ringo to bind p34cdc2 (most likely free p34cdc2 rather
than p34cdc2/cyclinB complexes) and up-regulate p34cdc2
kinase activity. This is likely to be a significant property
of p33ringo, as malE–p33ringo can activate GST–p34cdc2 in
vitro and the overexpression of kinase-inactive p34cdc2
K33R inhibits p33ringo-induced oocyte maturation.
Moreover, both p33ringo and cyclin B1 activate the his-
tone H1 kinase activity of p34cdc2 to a similar extent in
extracts prepared from baculovirus-infected insect cells.
In interphase Xenopus extracts, however, cyclin B1 in-
duces higher levels of histone H1 kinase activity than
p33ringo (data not shown). The reason for this difference
in behavior, depending on the source of the extract, re-
mains to be investigated. Proteins that are known to as-
sociate with p34cdc2 include A- and B-type cyclins,
which are regulatory and activating subunits of p34cdc2
(for review, see Kobayashi et al. 1991a; Jackman and
Pines 1997), and Suc1/Cks proteins, which may regulate
substrate recognition by the p34cdc2/cyclin complex (Pa-
tra and Dunphy 1998). We have found no significant se-
quence homology between these proteins and p33ringo.
Interestingly, there is at least one other example of a
protein, p35, that has no sequence homology to cyclins
but can bind to and activate p34cdc2-like cyclin-depen-
dent kinase 5 (cdk5; for review, see Lew and Wang 1995).
The only homology that we have detected between p35
and p33ringo is a region of 44 amino acids that is 24%
identical. Although the similarity is not very high, it is
intriguing that this region of p35 (amino acids 159–203)
is included in the p35 fragment that is as effective as
full-length p35 to induce a high level of histone H1 ki-
nase activity in recombinant cdk5 (Lew and Wang 1995).
Moreover, it appears that phosphorylation is not re-
quired for activation of cdk5 by p35 (Lew and Wang
1995), whereas Thr-161 phosphorylation is an essential
requirement for the activity of p34cdc2/cyclin B com-
plexes (for review, see Morgan 1997). It will be interest-
ing to investigate whether or not activation of p34cdc2 by
p33ringo involves Thr-161 phosphorylation.
While this paper was under revision, Lenormand et al.
(1999) reported the cloning of a Xenopus cDNA that
complements a rad1 mutant of Schizosaccharomyces
pombe and encodes a protein 98% identical to p33ringo
(ls27). They showed that this protein induces Xenopus
oocyte maturation and suggested that this might depend
on the activation of p42mpk1, but the mechanism was not
elucidated (Lenormand et al. 1999). As discussed above,
our results indicate that p33ringo probably induces oocyte
maturation via the activation of p34cdc2. This is consis-
tent with the ability of p33ringo to activate MPF in cy-
cloheximide-treated oocytes independently of p42mpk1
activation.
In conclusion, we have identified a novel p34cdc2-bind-
ing and activating protein that can potently trigger Xeno-
pus oocyte maturation. De novo synthesis of this protein
appears to be required for progesterone-induced matura-
tion. This may explain the requirement for the activa-
tion of free p34cdc2 during progesterone-induced matura-
tion, which was proposed based on the inhibitory effects
of dominant-negative p34cdc2 and a neutralizing anti-
p34cdc2 antibody (Nebreda et al. 1995). Because newly
synthesized cyclins are apparently not required for the
activation of MPF induced by progesterone (Minshull et
al. 1991; H. Hoccheger and T. Hunt, unpubl.), our results
suggest that p33ringo may be a crucial protein that needs
to be synthesized de novo upon progesterone stimulation
to initiate the meiotic maturation of oocytes. Further
work will be needed to determine the precise mecha-
nism by which p33ringo-activated p34cdc2 can induce pre-
MPF activation and what the possible connection be-
tween this pathway and the p39mos/p42mpk1 pathway
might be during oocyte maturation.
Materials and methods
Preparation of the Xenopus oocyte cDNA expression library
Stage VI Xenopus oocytes were stimulated with progesterone (5
µg/ml) and collected when ~ 50% of the oocytes had reached
GVBD. RNA was prepared using the Oligotex Direct mRNA kit
(Qiagen). Briefly, ~ 900 oocytes were incubated with collagenase
B (1 mg/ml, Sigma) for 1 hr in modified Barth’s medium
(mBarth) at room temperature followed by extensive washing in
PBS. The oocytes were lysed in 15 ml of OL1 lysis, diluted with
30 ml of ODB buffer, and poly(A)+ RNA was extracted by incu-
bation with 150 µl of Oligotex beads for 15 min at room tem-
perature. The beads were aliquoted (1.5 ml/tube), transferred to
spin columns, and washed twice with 0.5 ml of OW2 buffer (10
mMTris-HCl at pH 7.5, 150 mM NaCl, 1 mM EDTA. The RNA
was finally eluted with OEB buffer (preheated to 70°C), ethanol
precipitated, and resuspended in 5 mM Tris (pH 7.5). Double-
stranded cDNA was synthesized from 5 µg of poly(A)+ RNA
using a commercial cDNA synthesis kit (catalog no. 200400,
Stratagene) as recommended by the manufacturer. The cDNAs
longer than 500 bp were gel purified and directionally cloned
into the FTX5 expression vector (provided by C. Hill, ICRF,
London, UK) digested previously with EcoRI and XhoI. The li-
gation mixture was transformed into XL-1 Blue MRF8 electro-
poration-competent cells (Stratagene). We estimated that the
primary cDNA library consisted of ~ 120,000 transformants.
Screening of small pools of the cDNA expression library
by oocyte injection
The procedure to prepare small pools from the primary cDNA
library was essentially as described by Lustig et al. (1997). The
library was plated at ~ 150–200 transformants per plate [10 cm,
Luria–Bertani (LB) medium–ampicillin] and grown at 37°C over-
night. Colonies from each plate were recovered as a pool in 2 ml
of Terrific Broth from which 90 µl was used to prepare 20%
glycerol stocks while the remaining was used to isolate plasmid
DNA. The DNA from each pool was linearized with XbaI and in
vitro transcribed using the Megascript T7 transcription kit (Am-
bion) according to the manufacturer’s instructions. The mRNA
was purified by phenol–chloroform extraction followed by etha-
nol precipitation and finally dissolved in 40 µl of DEPC-treated
water. For the screening, ~ 80–100 ng of mRNA was injected into
stage VI oocytes that were incubated for ~ 30–36 hr to allow
translation of the injected mRNAs and scored for GVBD. The
groups of mRNA-injected oocytes that did not show GVBD
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were stimulated further with progesterone (5 µg/ml) and scored
for acceleration of maturation. We analyzed 105 pools and found
4 that were able to trigger GVBD on their own, whereas 22 pools
accelerated progesterone-induced maturation. All of the posi-
tive pools were analyzed by Southern blotting for the presence
of known inducers of oocyte maturation including p39mos (Sa-
gata et al. 1988), Cdc25 (Izumi et al. 1992; Kumagai and Dunphy
1992) and cyclins A1, A2, B1, B2, B3, B4, and B5 (provided by T.
Hunt and collaborators, ICRF, South Mimms, UK). Two posi-
tive pools that did not contain any of the above-mentioned
cDNAs were subdivided into smaller pools in two rounds, first
of 20 transformants and then single clones, from which plasmid
DNA and in vitro-transcribed mRNAs were prepared and in-
jected into oocytes as described above. Using this protocol we
isolated two clones that encoded Myc-tagged proteins and were
able to potently induce GVBD.
Isolation of full-length p33ringo cDNAs
Full-length cDNAs of the two clones isolated in the oocyte
expression screening were obtained from a l ZAP Xenopus oo-
cyte cDNA library (provided by J. Shuttleworth, University of
Birmingham, UK). The phage library was transferred onto nylon
membranes (Hybond N, Amersham) and probed independently
with the two 32P-labeled cDNAs (Megaprime, Amersham) in
Church buffer (0.5 M NaHPO4 at pH 7.2, 7% SDS, 1 mM EDTA,
10 grams/liter BSA) at 65°C for 16 hr. Several pBluescript
phagemids were isolated containing ORFs that overlapped with
the cDNAs isolated form the expression library. We selected as
full-length cDNAs those clones that extended farther at the 58
end and contained upstream stop codons followed by an ATG in
the same frame as the ORF. The accession numbers for the
full-length cDNAs are AJ133499 (ls26) and AJ133500 (ls27). The
cDNAs isolated in the oocyte expression screening started at
positions 246 (ls26) and 88 (ls27) of the corresponding full-
length clones.
Oocyte maturation
Stage VI oocytes were sorted after collagenase B treatment (Boe-
hringer Mannheim, 0.5 mg/ml, 30–60 min) and left at 18°C in
mBarth for 2–16 hr before injection. For the experiment in Fig-
ure 4, frogs were injected with pregnant mare’s serum gonado-
tropin (100 I.U., Intervet) 3 days prior to operation and the oo-
cytes were manually sorted. Meiotic maturation was induced by
incubation with 5 µg/ml progesterone (Sigma) or by injection
with 50 nl of either synthetic mRNAs or purified malE–p33ringo
(see below) or malE–p39mos (Nebreda and Hunt 1993) proteins.
In vitro-transcribed p39mos mRNA was obtained with the
MEGAscript kit (Ambion) from a construct prepared by sub-
cloning the full-length Xenopus c-mos proto-oncogene from
murine leukemia virus (MLV)–mos (Nebreda et al. 1993) into
FTX5. Maturation was scored by the appearance of a white spot
at the animal pole of the oocyte, and GVBD was confirmed after
fixation in 5% TCA.
Bacterial expression and purification of malE–p33ringo
fusion proteins
The p33ringo cDNAs from FTX5 were subcloned into the pMalc2
expression vector (New England Biolabs) digested with BamHI
and XbaI. For protein expression, the pMalc2–p33ringo con-
structs were transformed into Escherichia coli BL21(DE3). Fresh
overnight cultures in LB–ampicillin (100 µg/ml) were diluted
1000-fold and incubated further at 37°C until OD600 was 0.6–
0.8. The cultures were diluted 1:1 and induced with 100 µM
isopropyl-b-D-thiogalactopyranoside (IPTG) for 6 hr at 23°C.
Cells were collected, washed with cold PBS, and lysed in 50 mM
Tris (pH 7.5), 50 mM NaCl, 5 mM EDTA, 1 mM phenylmethyl-
sulfonyl fluoride (PMSF), and 1 mg/ml lysozyme for 30 min at
4°C. After sonication and centrifugation at 10,000g for 10 min,
the supernatant was supplemented with 1 mM dithiothreitol
(DTT) and incubated with amylose beads (New England Biolabs)
for 30 min at 4°C. Beads were washed twice in PBS and once in
50 mM Tris (pH 8), 50 mM NaCl, 1 mM DTT, followed by elution
with the same buffer supplemented with 0.1 mM EDTA and 12
mM maltose. The protein was finally dialyzed against 20 mM
Tris (pH 8), 50 mM NaCl, 0.1 mM EDTA, 0.5 mM DTT, and 5%
glycerol, stored at −70°C, and never subjected to more than two
rounds of freeze–thawing.
Histone H1 and MBP kinase assays
The oocytes were lysed in 10 µl per oocyte of ice-cold H1K
buffer [80 mM b-glycerophosphate (pH 7.5), 20 mM EGTA, 15
mM MgCl2, 1 mM DTT, 1 mM AEBSF) and centrifuged at 14,000
rpm (Eppendorf centrifuge) for 10 min. The supernatant (oocyte
lysate), equivalent to about half an oocyte, was incubated for 15
min at 22°C with 3 µg of either histone H1 or MBP in 12 µl of
H1K buffer supplemented with 2 µCi of [g-32P]ATP (3000 Ci/
mmole) and 50 µM cold ATP. The kinase reactions were ana-
lyzed by SDS-PAGE and autoradiography.
Immunoblotting and immunoprecipitation
Oocyte lysates were usually prepared in H1K buffer, as de-
scribed above, except for the detection of endogenous p33ringo,
where oocytes were lysed in 20 µl per oocyte of an ice-cold
buffer containing 80 mM b-glycerophosphate (pH 7.6), 50 mM
NaCl, 10 mM EDTA, 0.2 M sucrose, 2 mM PMSF, 1 µM micro-
cystin, 50 nM calyculin A, 10 µg/ml pepstatin A, and a protease
inhibitor cocktail (Complete, Boehringer Mannheim). The ly-
sate equivalent of about one oocyte per lane was separated by
SDS-PAGE and transferred to nitrocellulose membranes (0.22
µm Protran, Schleicher & Schuell) using a semidry blotting ap-
paratus (Hoefer). The membrane was blocked for 30–60 min at
room temperature in TTBS buffer (25 mM Tris-HCl at pH 8.0,
150 mM NaCl, 0.05% Tween 20) supplemented with 4% nonfat
dry milk and probed with the corresponding antibody in TTBS
supplemented with 1% milk, usually overnight at 4°C. The
monoclonal antibody 3E1 (provided by J. Gannon and T. Hunt,
ICRF, South Mimms, UK) was used to detect p34cdc2 (Nebreda
et al. 1995), and the rabbit antiserum 3297.1 was used for the
detection of p42mpk1 (Palmer et al. 1998). For p39mos we used a
purified rabbit antibody (C-237, Santa Cruz Biotechnology) and
for His-tagged cyclin B a monoclonal anti-penta-His antibody
(Qiagen). Xenopus cyclins B1 and B4 were detected with affin-
ity-purified antibodies provided by H. Hoccheger and T. Hunt
(ICRF, South Mimms, UK). The anti-p33ringo antibodies were
prepared in rabbits against bacterially produced malE–p33ringo
protein and were affinity purified on a GST–p33ringo-containing
nitrocellulose strip as described (Harlow and Lane 1988). In all
cases, horseradish peroxidase-coupled secondary antibodies
(Dakko) were used, and the binding was detected using the en-
hanced chemiluminescence detection system (Amersham).
For immunoprecipitation, groups of 25 oocytes were labeled
in mBarth containing 1 mCi/ml of [35S]methionine for 14 hr.
The oocytes were washed three times in mBarth and lysed in
H1K buffer (10 µl/oocyte) supplemented with 2 µM microcystin,
2.5 mM benzamidine–HCl, 10 µg/ml each of aprotinin, leupep-
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tin, and pepstatin A, and the Complete protease inhibitor cock-
tail (Boehringer Mannheim). The oocyte lysates were precleared
with 25 µl of protein A–Sepharose beads for 2 hr at 4°C and
then incubated with 3 µl of either preimmune serum or a
rabbit antiserum prepared against the KLH-coupled peptides
THDLHILQE and DGTALEWHHL corresponding to residues
near the carboxyl terminus of p33ringo (ls26). After 90 min at
4°C, the lysates were mixed with 100 µl of a 10% solution of
protein A–Sepharose beads in IP buffer (50 mM Tris-HCl at pH
7.5, 150 mM NaCl, 20 mM NaF, 5 mM EDTA, 5 mM EGTA, 100
µM sodium–vanadate, 1% NP-40), supplemented with micro-
cystin and protease inhibitors as indicated above, and incubated
further overnight at 4°C. The beads were washed four times in
IP buffer, transferred to a new tube, and boiled in SDS sample
buffer for elution of the immunocomplexes, which were ana-
lyzed by SDS-PAGE and autoradiography.
Antisense experiments
We designed four antisense oligonucleotides based on sequences
around the first ATG of either ls27 (1-TGCATATGCCTCA-
TTGTAGAAAGG and 2-AACTAAGGTGGCCCGGGTTG-
CACT) or ls26 (4-ACTCTGCATGTGCCTCATTGTAGA and
5-AATGGAGCTGGCCCGGGTTACACT) and three antisense
oligonucleotides based on sequences common to the 58 region
of both the ls26 and ls27 p33ringo cDNAs (3-TTTTCGCCTTG-
CGCGCTCCAA; 6-ATATGCTAGAACCATTGCTATGAGA
and 7-TCATTTTCTAGGAGCCTGTA). The two control oligo-
nucleotides were a randomized sequence (8-TAGAGAAGAT-
AATCGTCATCTTA) and the same sequence as antisense 4 but
with four point mutations (9-ACTCTTCATCTGCCTCTTT-
GTCGA).
Oligonucleotides were prepared on an automatic DNA syn-
thesizer using a special solid support carrying dimethoxytrityl
(DMT)-protected 1,3-propanediol linked to amino-controlled
pore glass through a standard succinil linkage (Van Aerschot et
al. 1995) and the appropriate protected nucleoside phosphora-
midites. The 200 nmole scale synthesis cycle was used. Oligo-
nucleotide supports were treated with 1 ml of a concentrated
ammonia solution (32%) at 55°C for 16 hr. The solid support
was removed by filtration and the solution was concentrated to
dryness. The residue was passed through a Dowex 50Wx4 Na+
(Fluka) to exchange the ammonium to sodium counterions. Fi-
nally, oligonucleotides were desalted on Sephadex G-25 (NAP-
10 columns, Pharmacia-Upjohn), eluted with water, and con-
centrated using a Speed-vac rotatory evaporator until ~ 2 mg/ml.
The ability of the antisense oligonucleotides to target the ls26
and ls27 p33ringo mRNAs was tested in vitro using rabbit reticu-
locyte lysates as described (Minshull and Hunt 1992). In vitro-
transcribed mRNAs were added at a concentration of 10 µg/ml
to rabbit reticulocyte lysates (10 µl, Promega) and incubated for
30 min at 30°C in the presence of the oligonucleotides (10 µg/
ml), RNase H (0.2 U/µl, GIBCO–BRL) and [35S]methionine (0.5
mCi/ml, >1000 Ci/mmole). The 35S-labeled proteins were ana-
lyzed by SDS-PAGE and autoradiography. To test the effect of
the oligonucleotides in oocyte maturation, oocytes were in-
jected with ~ 100 ng of each oligonucleotide and incubated for
5–6 hr prior to stimulation with progesterone (5 µg/ml) and/or
injection of malE–p33ringo (2.5–10 ng per oocyte).
Northern blots
Total RNA was extracted from oocytes using the Triazol one-
step extraction method (GIBCO) following the manufacturer’s
protocol. About 20 µg of RNA was separated on a 1.2% agarose
gel (20 mM MOPS, 5 mM sodium acetate, 1 mM EDTA, 2%
formaldehyde), transferred to a nylon membrane (GeneScreen
Plus, Nitran), and UV cross-linked. The probes were an 0.8-kb
BamHI–BamHI DNA fragment that includes most of the ls26
p33ringo ORF and hybridizes to both the ls26 and ls27 cDNAs,
and a 1-kb NcoI–XhoI DNA fragment including the p39mos ORF.
For the hybridization, the DNA probes were labeled with
[32P]dCTP (3000 Ci/mmole) and incubated with the RNA blot
in Church buffer at 55°C for 14 hr. After four washes for 10 min
at 55°C (two in 2× SSC, 0.1% SDS, and two in 0.5× SSC, 0.1%
SDS), the blot was subjected to autoradiography.
Amylose pull-downs
Extracts from Sf9 insect cells expressing p34cdc2 were prepared
as described (Kumagai and Dunphy 1997). The extracts (usually
20 µl) were diluted 1:5 in HBS buffer (10 mM HEPES–KOH at pH
7.4, 150 mM NaCl, 1% BSA, 1 mM PMSF, 10 µg/ml aprotinin, 10
µg/ml leupeptin) and incubated for 20 min at room temperature
with different concentrations of either malE or malE–p33ringo
prebound to 10 µl of amylose beads. In some experiments, amy-
lose pull-downs were performed in the presence of purified His-
tagged cyclin B1 (Kumagai and Dunphy 1997) either alone or in
combination with the p34cdc2-containing extracts. After cen-
trifugation, the beads were washed four times in IP buffer and
once in HBS buffer, and analyzed by immunoblotting.
For rabbit reticulocyte pulldowns, pET8c–p34cdc2 (Nebreda et
al. 1995), pGEM1–cyclin B1 and pGEM1–cyclin B2 (provided by
H. Hoccheger and T. Hunt) and FTX5–p42mpk1 (Gavin and Ne-
breda 1999) were in vitro-transcribed and -translated in a
coupled reticulocyte lysate system (TNT-T7, Promega) in the
presence of [35S]methionine. Aliquots of the reticulocyte lysates
(20 µl) were diluted 1:10 in IP buffer supplemented with 1%
BSA, 1 mM PMSF, and 10 µg/ml of both aprotinin and leupeptin
and incubated for 40 min at 20°C with 1 µg of malE or malE–
p33ringo prebound to 5 µl of amylose beads. The beads were
washed six times in ice-cold IP buffer and analyzed by SDS-
PAGE and autoradiography.
For pull-downs with oocyte extracts, 200 µl of extract pre-
pared using 2 µl of H1K buffer per oocyte was diluted 1:1 in IP
buffer supplemented with 1% BSA and incubated with 3 µg of
malE or malE–p33ringo prebound to 15 µl of amylose beads. After
1 hr at 20°C, the beads were washed six times in IP buffer,
resuspended in 20 µl of HBS buffer, and 4 µl was analyzed by
immunoblotting with anti-p34cdc2 and anti-p42mpk1 antibodies.
Activation of p34cdc2 by p33ringo in cell-free extracts
and in vitro
High speed oocyte extracts were obtained from immature oo-
cytes using 2 µl per oocyte of H1K buffer supplemented with 10
mM DTT, an ATP-regenerating mixture, and 1 µg/ml cyclohexi-
mide as described (Karaiskou et al. 1998). The extract (25 µl) was
preincubated with water or 5 mM vanadate for 5 min prior to the
addition of malE (1 µg), malE–p33ringo (0.6 µg), and/or GST–
XCdc25 (0.2 µg). Aliquots of 5 µl were used for histone H1
kinase assay and immunoblotting with anti-p34cdc2 antibodies.
Extracts (5 µl) prepared from baculovirus-infected Sf9 cells
expressing either wild-type p34cdc2 or kinase-inactive p34cdc2
K33R were diluted 1:5 in HBS buffer supplemented with 250 µM
ATP and 10 mM MgCl2, incubated for 20 min at room tempera-
ture with various concentrations of malE, malE–p33ringo, or His-
–cyclin B and analyzed by histone H1 kinase assay. For p13suc1
pull-downs, 100 µl of the extracts incubated with malE, malE–
p33ringo, or His–cyclin B as above were mixed with 10 µl of
p13suc1 linked to agarose beads (Calbiochem) for 30 min at 4°C.
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The beads were washed four times in IP buffer and once in HBS
buffer, and then assayed for histone H1 kinase activity.
For the in vitro activation, 1.5 µg of bacterially expressed
GST–p34cdc2 (Nebreda et al. 1995) was incubated in 15 µl of
interphase Xenopus cell-free extracts prepared from activated
eggs. After 40 min at 22°C, the extracts were diluted 10-fold in
HIK buffer and incubated further with 5 µl of glutathione–Seph-
arose beads for 90 min at 4°C. The beads were washed four
times in IP buffer and once in H1K buffer, resuspended in 5 µl of
H1K buffer and incubated with 2 µg of purified malE, malE–
p33ringo, or His–cyclin B for 20 min at 22°C. Half of the sample
was then assayed for histone H1 kinase activity.
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